Positive
●
Proactive Investors
●
3 months ago
Jefferies has resumed coverage of GSK PLC (LSE:GSK, NYSE:GSK) with a buy rating and a 2,500p price target, implying roughly 30% upside from the 1,916.50p close. The broker argues a run of business development deals has brought the drugmaker's £40 billion 2031 revenue target within reach without straining the profit and loss account.